Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Income towards Parent Company (2021 - 2026)

MoonLake Immunotherapeutics' Income towards Parent Company history spans 6 years, with the latest figure at -$69.7 million for Q1 2026.

  • Quarterly Income towards Parent Company fell 71.87% to -$69.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$259.5 million through Mar 2026, down 75.52% year-over-year, with the annual reading at -$230.3 million for FY2025, 89.96% down from the prior year.
  • Income towards Parent Company came in at -$69.7 million for Q1 2026, down from -$63.0 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$7.9 million in Q4 2023 to a low of -$70.7 million in Q3 2025.
  • The 5-year median for Income towards Parent Company is -$17.4 million (2022), against an average of -$31.2 million.
  • The largest YoY upside for Income towards Parent Company was 69.3% in 2022 against a maximum downside of 20715.22% in 2022.
  • MoonLake Immunotherapeutics' Income towards Parent Company stood at -$16.5 million in 2022, then soared by 52.11% to -$7.9 million in 2023, then tumbled by 488.23% to -$46.4 million in 2024, then crashed by 35.83% to -$63.0 million in 2025, then fell by 10.61% to -$69.7 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Income towards Parent Company are -$69.7 million (Q1 2026), -$63.0 million (Q4 2025), and -$70.7 million (Q3 2025).